CERN
$70.67
Cerner
($.81)
(1.13%)
Earnings Details
1st Quarter March 2019
Thursday, April 25, 2019 4:01:00 PM
Tweet Share Watch
Summary

Cerner Beats

Cerner (CERN) reported 1st Quarter March 2019 earnings of $0.62 per share on revenue of $1.4 billion. The consensus earnings estimate was $0.61 per share on revenue of $1.4 billion. The Earnings Whisper number was $0.61 per share. Revenue grew 7.5% on a year-over-year basis.

The company said it expects second quarter non-GAAP earnings of $0.63 to $0.65 per share on revenue of $1.41 billion to $1.46 billion. The current consensus earnings estimate is $0.64 per share on revenue of $1.45 billion for the quarter ending June 30, 2019. The company also said it now expects 2019 earnings of $2.64 to $2.72 per share and continues to expect revenue of $5.65 billion to $5.85 billion. The company's previous guidance was earnings of $2.57 to $2.67 per share and the current consensus earnings estimate is $2.65 per share on revenue of $5.74 billion for the year ending December 31, 2019.

Cerner Corp is a supplier of health care information technology, and offers software, professional services, medical device integration, remote hosting and employer health and wellness services.

Results
Reported Earnings
$0.62
Earnings Whisper
$0.61
Consensus Estimate
$0.61
Reported Revenue
$1.39 Bil
Revenue Estimate
$1.39 Bil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Cerner Reports First Quarter 2019 Results

KANSAS CITY, Mo., April 25, 2019 (GLOBE NEWSWIRE) -- Cerner Corporation (Nasdaq: CERN) today announced results for the 2019 first quarter that ended March 30, 2019.

Bookings in the first quarter of 2019 were in-line with the Company’s expectations at $1.242 billion.

First quarter 2019 revenue was $1.390 billion, an increase of 8 percent compared to $1.293 billion in the first quarter of 2018. 

On a U.S. Generally Accepted Accounting Principles (GAAP) basis, first quarter 2019 net earnings were $166.2 million and diluted earnings per share were $0.51.  First quarter 2018 GAAP net earnings were $160.0 million and diluted earnings per share were $0.48.   

Adjusted Net Earnings for first quarter 2019 were $198.5 million, compared to $193.9 million of Adjusted Net Earnings in the first quarter of 2018.  Adjusted Diluted Earnings Per Share were $0.61 in the first quarter of 2019 compared to $0.58 of Adjusted Diluted Earnings Per Share in the year-ago quarter.    

Adjusted Net Earnings and Adjusted Diluted Earnings Per Share are not recognized terms under GAAP.  These non-GAAP financial measures should not be substituted for GAAP net earnings or GAAP diluted earnings per share, respectively, as measures of Cerner’s performance, but instead should be utilized as supplemental measures of financial performance in evaluating our business.  Please see the accompanying schedule, titled “Reconciliation of GAAP Results to Non-GAAP Results,” where our non-GAAP financial measures are defined and reconciled to the most comparable GAAP measures.

Other Highlights:

  • First quarter operating cash flow of $317.3 million.
  • First quarter Free Cash Flow of $123.5 million.  Free Cash Flow is a non-GAAP financial measure defined as GAAP cash flows from operating activities less capital purchases and capitalized software development costs.  Please see the accompanying schedule, titled “Reconciliation of GAAP Results to Non-GAAP Results.”
  • First quarter days sales outstanding of 76 days, down from 79 days in the fourth quarter of 2018 and up from 73 days in the year-ago quarter.
  • Total backlog of $14.87 billion

“I am pleased with our first quarter results, which were in line with our expectations,” said Brent Shafer, Chairman and CEO.  “During the quarter, we rolled out a refined operating model, which is designed to improve our operating efficiency and speed value creation for our clients.  These refinements are foundational to significant improvements in profitably we expect to deliver as part of recently announced operational improvement initiatives.  Collectively, our operational improvement initiatives, recently announced dividend program, and expanded share repurchase program underscore our commitment to creating value for clients and shareholders.”

Future Period Guidance
Cerner currently expects:

  • Second quarter 2019 revenue between $1.410 billion and $1.460 billion.
  • Full year 2019 revenue between $5.650 billion and $5.850 billion, consistent with previously provided full year guidance.
  • Second quarter 2019 Adjusted Diluted Earnings Per Share between $0.63 and $0.65.*
  • For full-year 2019 Adjusted Diluted Earnings Per Share, the Company expects to benefit from the operational improvement initiatives and expanded share repurchase program announced on April 9, 2019.  The amount of the benefit will depend on the timing of operational improvements and share repurchases, but based on preliminary estimates, the Company expects full-year 2019 Adjusted Diluted Earnings Per Share to be between $2.64 and $2.72*, which is above the previously provided guidance range of $2.57 to $2.67.* 
  • Second quarter 2019 new business bookings between $1.250 billion and $1.450 billion.

    *Future period non-GAAP guidance includes adjustments for items not indicative of our core operations, which may include, without limitation, share-based compensation expense, organizational restructuring and other expense and acquisition-related expenses.  Such adjustments may be affected by changes in ongoing assumptions and judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains or other items that may not directly correlate to the underlying performance of our business operations.  The exact amounts of these adjustments are not currently determinable, but may be significant.  It is therefore not practicable to provide the comparable GAAP measures or reconcile this non-GAAP guidance to the most comparable GAAP measures.

Earnings Conference Call
Cerner will host an earnings conference call to provide additional detail on the Company’s results and outlook at 3:30 p.m. CT on April 25, 2019.  On the call, Cerner will discuss its first quarter 2019 results and answer questions from the investment community.  The call may also include discussion of Cerner developments, and forward-looking and other material information about business and financial matters.  The dial-in number for the conference call is (678)-509-7542; the passcode is Cerner.  Cerner recommends joining the call 15 minutes early for registration.  

An audio webcast will be available live and archived on Cerner’s website at www.cerner.com under the About Us section (click Investor Relations, then Presentations and Webcasts).

About Cerner
Cerner’s health technologies connect people and information systems at more than 27,500 contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers an integrated clinical and financial system to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit Cerner.com, The Cerner Blog or connect on Facebook, Instagram, LinkedIn, Twitter or The Cerner Podcast Nasdaq: CERN. Smarter Care. Better Outcomes. Healthier You.

Certain trademarks, service marks and logos set forth herein are property of Cerner Corporation and/or its subsidiaries.

All statements in this press release that do not directly and exclusively relate to historical facts constitute forward-looking statements. These forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner’s management with respect to future events and are subject to a number of significant risks and uncertainties. It is important to note that Cerner's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. The words “expect”, “expected”, “expectations”, “believe”, “belief,” “plans”, “anticipate,” “opportunities,” “continue,” “potential,” “should,” “could”, “will,” “target,” “view,” “estimates”, “guidance”, “designed”, “position”, “targets”, “projected”, “intend”, “forecast” or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. For example, our forward-looking statements include statements regarding future period guidance. Factors that could cause or contribute to such differences include, but are not limited to: possibility of significant costs and reputational harm related to product related liabilities; potential claims for system errors and warranties; the possibility of interruption at our data centers or client support facilities, or those of third parties with whom we have contracted (such as public cloud providers), that could expose us to significant costs and reputational harm; the possibility of increased expenses, exposure to legal claims and regulatory actions and reputational harm associated with a cyberattack or other breach in our IT security or the IT security of third parties on which we rely; our proprietary technology may be subject to claims for infringement or misappropriation of intellectual property rights of others, or may be infringed or misappropriated by others; potential claims or other risks associated with relying on open source software in our proprietary software solutions or technology-enabled services; material adverse resolution of legal proceedings or other claims; risks associated with our global operations, including without limitation greater difficulty in collecting accounts receivable; risks associated with fluctuations in foreign currency exchange rates; changes in tax laws, regulations or guidance that could adversely affect our tax position and/or challenges to our tax positions in the U.S. and non-U.S. countries; the uncertainty surrounding the impact of the United Kingdom’s vote to leave the European Union (commonly referred to as Brexit) on our global business; risks associated with the unexpected loss or recruitment and retention of key personnel or the failure to successfully develop and execute succession planning to assure transitions of key associates and their knowledge, relationships and expertise; risks associated with failure to timely or effectively manage publicity related to harassment or discrimination claims and legal proceedings if such claims are raised against key personnel; risks related to our dependence on strategic relationships and third-party suppliers; risks inherent with business acquisitions and combinations and the integration thereof into our business or relating to disputes involving such acquisitions or combinations; risks associated with volatility and disruption resulting from global economic or market conditions; significant competition and our ability to quickly respond to market changes, changing technologies and evolving pricing and deployment methods and to bring competitive new solutions, devices, features and services to market in a timely fashion; managing growth in the new markets in which we offer solutions, health care devices or services; long sales cycles for our solutions and services; risks inherent in contracting with government clients, including without limitation, complying with strict compliance and disclosure obligations, navigating complex procurement rules and processes and defending against bid protests; risks associated with our outstanding and future indebtedness, such as compliance with restrictive covenants, which may limit our flexibility to operate our business; changes in accounting standards issued by the Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements; the potential for losses resulting from asset impairment charges; changing political, economic, regulatory and judicial influences, which could impact the purchasing practices and operations of our clients and increase costs to deliver compliant solutions and services; non-compliance with laws, government regulation or certain industry initiatives or failure to deliver solutions or services that enable our clients to comply with laws or regulations applicable to their businesses; variations in our quarterly operating results; potential variations in our sales forecasts compared to actual sales; volatility in the trading price of our common stock and the timing and volume of market activity; inability to reduce expenses and costs to the extent currently anticipated; risks that Cerner’s revenue growth may be lower than anticipated and/or that the mix of revenue shifts to low margin revenue; risks that our stock repurchase program or quarterly dividend program will not be fully implemented or enhance long-term shareholder value; risks that Cerner’s business may be negatively affected as a result of future proxy fights or the actions of activist shareholders; and our directors’ authority to issue preferred stock and the anti-takeover provisions in our corporate governance documents. Additional discussion of these and other risks, uncertainties and factors affecting Cerner’s business is contained in Cerner’s filings with the Securities and Exchange Commission. The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. Except as required by law, Cerner undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes in our business, results of operations or financial condition over time.

Investor Contact:  Allan Kells, (816) 201-2445, akells@cerner.com
Media Contact:  Misti Preston, (816) 299-2037, misti.preston@cerner.com  
Cerner’s Internet Home Page:  www.cerner.com  

    
CERNER CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the three months ended March 30, 2019 and March 31, 2018
(unaudited)
    
(In thousands, except per share data) Three Months Ended
  20192018
    
Revenues $1,389,877 $1,292,861 
Costs of revenue  253,204  231,278 
Margin  1,136,673  1,061,583 
    
Operating expenses   
Sales and client service  640,187  589,948 
Software development  180,361  161,617 
General and administrative  96,196  92,294 
Amortization of acquisition-related intangibles  21,985  22,509 
Total operating expenses  938,729  866,368 
    
Operating earnings  197,944  195,215 
    
Other income, net  8,432  4,864 
    
Earnings before income taxes  206,376  200,079 
Income taxes  (40,157) (40,078)
Net earnings $166,219 $160,001 
    
Basic earnings per share $0.51 $0.48 
    
Basic weighted average shares outstanding  324,573  332,395 
    
Diluted earnings per share $0.51 $0.48 
    
Diluted weighted average shares outstanding  327,003  336,534 
    
Note 1: Our revenues by business model for the three months ended March 30, 2019 and March 31, 2018 were as follows:
    
(In thousands) Three Months Ended
  20192018
    
Licensed software $154,477 $134,819 
Technology resale  55,540  63,376 
Subscriptions  84,291  76,636 
Professional services  490,439  441,268 
Managed services  304,393  268,305 
Support and maintenance  276,963  284,564 
Reimbursed travel  23,774  23,893 
Total revenues $1,389,877 $1,292,861 
    

 

CERNER CORPORATION AND SUBSIDIARIES 
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS 
For the three months ended March 30, 2019 and March 31, 2018
(unaudited)
    
ADJUSTED OPERATING EXPENSES
    
(In thousands) Three Months Ended
  20192018
    
Operating expenses (GAAP) $938,729 $866,368 
    
Share-based compensation expense  (21,589) (26,457)
Health Services acquisition-related amortization  (21,097) (21,208)
Organizational restructuring and other expense  (2,392)  
    
Adjusted Operating Expenses (non-GAAP) $893,651 $818,703 
    
ADJUSTED OPERATING EARNINGS AND ADJUSTED OPERATING MARGIN
    
(In thousands) Three Months Ended
  20192018
    
Operating earnings (GAAP) $197,944 $195,215 
    
Share-based compensation expense  21,589  26,457 
Health Services acquisition-related amortization  21,097  21,208 
Organizational restructuring and other expense  2,392   
    
Adjusted Operating Earnings (non-GAAP) $243,022 $242,880 
    
Operating Margin (GAAP)  14.24% 15.10%
    
Adjusted Operating Margin (non-GAAP)  17.49% 18.79%
    
ADJUSTED NET EARNINGS AND ADJUSTED DILUTED EARNINGS PER SHARE
    
(In thousands, except per share data) Three Months Ended
  20192018
    
Net earnings (GAAP) $166,219 $160,001 
    
Pre-tax adjustments for Adjusted Net Earnings:   
Share-based compensation expense  21,589  26,457 
Health Services acquisition-related amortization  21,097  21,208 
Organizational restructuring and other expense  2,392   
    
After-tax adjustments for Adjusted Net Earnings:   
Income tax effect of pre-tax adjustments  (8,771) (9,548)
Share-based compensation permanent tax items  (3,997) (4,189)
    
Adjusted Net Earnings (non-GAAP) $198,529 $193,929 
    
Diluted weighted average shares outstanding  327,003  336,534 
    
Adjusted Diluted Earnings Per Share (non-GAAP) $0.61 $0.58 
    
FREE CASH FLOW
    
(In thousands) Three Months Ended
  20192018
    
Cash flows from operating activities (GAAP) $317,266 $408,965 
Capital purchases  (119,261) (79,711)
Capitalized software development costs  (74,551) (73,602)
Free Cash Flow (non-GAAP) $123,454 $255,652 
    
Cash flows from investing activities (GAAP) $(183,655)$(211,498)
    
Cash flows from financing activities (GAAP) $(6,991)$(154,311)
    
Explanation of Non-GAAP Financial Measures   
    
We report our financial results in accordance with accounting principles generally accepted in the United States of America ("GAAP"). However, we supplement our GAAP results with certain non-GAAP financial measures, which we believe enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational and economic performance. These non-GAAP financial measures are not meant to be considered in isolation, as a substitute for, or superior to GAAP results and investors should be aware that non-GAAP measures have inherent limitations and should be read only in conjunction with Cerner's consolidated financial statements prepared in accordance with GAAP. These non-GAAP measures may also be different from similar non-GAAP financial measures used by other companies and may not be comparable to similarly titled captions of other companies due to potential inconsistencies in the method of calculations. We provide the measures of Adjusted Operating Expenses, Adjusted Operating Earnings, Adjusted Operating Margin, Adjusted Net Earnings and Adjusted Diluted Earnings Per Share as such measures are used by management, along with GAAP results, to analyze Cerner's business, make strategic decisions, assess long-term trends on a comparable basis,and for management compensation purposes. We provide the measure of Free Cash Flow as such measure takes into account certain capital expenditures necessary to operate our business. Free Cash Flow is used by management, along with GAAP results, to analyze our earnings quality and overall cash generation of the business, and for management compensation purposes.
    
We calculate each of our non-GAAP financial measures as follows:
    
Adjusted Operating Expenses - Consists of GAAP operating expenses adjusted for: (i) share-based compensation expense, (ii) Health Services acquisition-related amortization, and (iii) organizational restructuring and other expense.
    
Adjusted Operating Earnings - Consists of GAAP operating earnings adjusted for: (i) share-based compensation expense, (ii) Health Services acquisition-related amortization, and (iii) organizational restructuring and other expense.
    
Adjusted Operating Margin - Consists of Adjusted Operating Earnings, as defined above, divided by revenues, in the applicable period; the result presented as a percentage.
    
Adjusted Net Earnings - Consists of GAAP net earnings adjusted for: (i) share-based compensation expense, (ii) Health Services acquisition-related amortization, (iii) organizational restructuring and other expense,  (iv) the income tax effect of the aforementioned items, and (v) share-based compensation permanent tax items.
    
Adjusted Diluted Earnings Per Share - Consists of Adjusted Net Earnings, as defined above, divided by diluted weighted average shares outstanding, in the applicable period.
    
Free Cash Flow - Consists of GAAP cash flows from operating activities, less capital purchases and capitalized software development costs.
    
Adjustments included in the calculations of Adjusted Operating Expenses, Adjusted Operating Earnings, and Adjusted Net Earnings are described below:
    
Share-based compensation expense - Non-cash expense arising from our equity compensation and stock purchase plans available to our associates and directors. We exclude share-based compensation expense as we believe the amount of such non-cash expenses in any specific period may not directly correlate to the underlying performance of our business operations. Share-based compensation expense is included in our Condensed Consolidated Statements of Operations as follows:
    
(In thousands) Three Months Ended
  20192018
    
Sales and client service $10,671 $12,579 
Software development  5,156  5,425 
General and administrative  5,762  8,453 
Total share-based compensation expense $21,589 $26,457 
    
Health Services acquisition-related amortization - Non-cash expense consisting of the amortization of customer relationships, acquired technology, and trade name intangible assets recorded in connection with our acquisition of the Health Services business in February 2015. We exclude Health Services acquisition-related amortization as we believe the amount of such non-cash expenses in any specific period may not directly correlate to the underlying performance of our business operations. Such amount is included in our Condensed Consolidated Statements of Operations in the caption "Amortization of acquisition-related intangibles."
    
Organizational restructuring and other expense - Consists of certain charges incurred in connection with our operational improvement initiatives. Expenses in connection with these efforts may include, but are not limited to, consultant and other professional services fees, employee separation costs, contract termination costs, and other such related expenses. We exclude organizational restructuring and other expense as we believe the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations. Such amount is included in our Condensed Consolidated Statements of Operations in the caption "General and administrative" expense.
    
Income tax effect of pre-tax adjustments - The GAAP effective income tax rate for the applicable quarterly period is applied to pre-tax adjustments for Adjusted Net Earnings.
    
Share-based compensation permanent tax items - Consists of permanent items impacting the Company's income tax provision related to our share-based compensation arrangements, including net excess tax benefits recognized upon the exercise of stock options. We exclude such items as we believe the amount of such items in any specific period may not directly correlate to the underlying performance of our business operations. Such amount is included in our Condensed Consolidated Statements of Operations in the caption "Income taxes."
    

 

CERNER CORPORATION AND SUBSIDIARIES 
CONDENSED CONSOLIDATED BALANCE SHEETS 
As of March 30, 2019 and December 29, 2018 
(unaudited)
   
(In thousands)20192018
   
Assets  
Current assets:  
Cash and cash equivalents$503,161 $374,126 
Short-term investments 400,509  401,285 
Receivables, net 1,159,215  1,183,494 
Inventory 24,104  25,029 
Prepaid expenses and other 336,817  334,870 
Total current assets 2,423,806  2,318,804 
   
Property and equipment, net 1,790,116  1,743,575 
Right-of-use assets 134,137   
Software development costs, net 915,149  894,512 
Goodwill 846,740  847,544 
Intangible assets, net 385,128  405,305 
Long-term investments 283,596  300,046 
Other assets 219,840  198,850 
Total assets$6,998,512 $6,708,636 
   
Liabilities and Shareholders’ Equity  
Current liabilities:  
Accounts payable$290,947 $293,534 
Current installments of long-term debt and capital lease obligations   4,914 
Deferred revenue 337,811  399,189 
Accrued payroll and tax withholdings 230,407  195,931 
Other current liabilities 81,459  69,122 
Total current liabilities 940,624  962,690 
   
Long-term debt and capital lease obligations 438,823  438,802 
Deferred income taxes 343,788  336,379 
Other liabilities 146,128  42,376 
Total liabilities 1,869,363  1,780,247 
   
Shareholders’ Equity:  
Common stock 3,629  3,622 
Additional paid-in capital 1,591,138  1,559,562 
Retained earnings 5,742,744  5,576,525 
Treasury stock (2,107,768) (2,107,768)
Accumulated other comprehensive loss, net (100,594) (103,552)
Total shareholders’ equity 5,129,149  4,928,389 
Total liabilities and shareholders’ equity$6,998,512 $6,708,636 
   

 

CERNER CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
For the three months ended March 30, 2019 and March 31, 2018
(unaudited)
    
  Three Months Ended
(In thousands) 20192018
    
CASH FLOWS FROM OPERATING ACTIVITIES:   
Net earnings $166,219 $160,001 
Adjustments to reconcile net earnings to net cash provided by operating activities:   
Depreciation and amortization  166,671  152,592 
Share-based compensation expense  19,860  24,935 
Provision for deferred income taxes  3,998  (3,047)
Changes in assets and liabilities:   
Receivables, net  13,789  (70,608)
Inventory  928  1,445 
Prepaid expenses and other  (13,318) 125,550 
Accounts payable  (10,891) 7,608 
Accrued income taxes  4,256  7,195 
Deferred revenue  (61,547) (7,205)
Other accrued liabilities  27,301  10,499 
    
Net cash provided by operating activities  317,266  408,965 
    
CASH FLOWS FROM INVESTING ACTIVITIES:   
Capital purchases  (119,261) (79,711)
Capitalized software development costs  (74,551) (73,602)
Purchases of investments  (90,953) (151,387)
Sales and maturities of investments  110,104  101,674 
Purchase of other intangibles  (8,994) (8,472)
    
Net cash used in investing activities  (183,655) (211,498)
    
CASH FLOWS FROM FINANCING ACTIVITIES:   
Repayment of long-term debt    (75,000)
Proceeds from exercises of stock options  15,281  10,036 
Payments to taxing authorities in connection with shares directly withheld from associates  (1,730) (1,723)
Treasury stock purchases  (20,542) (87,624)
    
Net cash used in financing activities  (6,991) (154,311)
    
Effect of exchange rate changes on cash and cash equivalents  2,415  (680)
    
Net increase in cash and cash equivalents  129,035  42,476 
Cash and cash equivalents at beginning of period  374,126  370,923 
    
Cash and cash equivalents at end of period $503,161 $413,399 
    

Cerner_RGB_Standard_ horizontal.png

Source: Cerner Corporation